Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1480P - Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States


16 Sep 2021


ePoster Display


George Kim


Annals of Oncology (2021) 32 (suppl_5): S1084-S1095. 10.1016/annonc/annonc709


G. Kim1, P. Cockrum2, A. Surinach3, S. Wang4, N. Lamarre4

Author affiliations

  • 1 Hematology And Oncology, George Washington University, 000 - Washington D.C./US
  • 2 Heor, Ipsen Biopharmaceuticals Inc., 02142 - Cambridge/US
  • 3 Evidence Strategy, Genesis Research, 07030 - Hoboken/US
  • 4 Real World Evidence Analytics, Genesis Research, 07030 - Hoboken/US

Abstract 1480P


The NAPOLI-1 study, a randomized phase III study in pts with mPDAC previously treated with gemcitabine-based therapy, demonstrated an improvement in progression-free survival (PFS) with liposomal irinotecan + 5-fluorouracil/ leucovorin (5-FU/LV) vs. 5-FU/LV. Pts treated with liposomal irinotecan + 5-FU/LV in NAPOLI-1 had a median age of 63 years at treatment (tx) initiation, 97% had performance scores (PS) equivalent to ECOG 0-1, and 34% had at least 2 prior lines of therapy. This study examines the characteristics and real-world (rw) PFS of pts with mPDAC treated with liposomal irinotecan regimens.


This retrospective study utilized the Flatiron Health EHR-derived database. Data were analyzed for adult pts with mPDAC treated with liposomal irinotecan-based regimens between January 2016 and October 2020. Pt and clinical characteristics evaluated included age, sex, stage at diagnosis, ECOG PS, and the number of prior lines of therapy at the time of tx initiation. rwPFS was assessed from the start of tx until progression or death. Median rwPFS was derived utilizing Kaplan-Meier methods.


675 pts with mPDAC treated with a liposomal irinotecan-based regimen were included. Of these, 54% were initially diagnosed with stage IV disease, 52% were male, and 62% initiated liposomal irinotecan in the 1L or 2L setting. Median age at tx initiation was 69 (IQR: 62 – 75) years. 91.5% of pts were treated in the community setting. Among pts with available ECOG PS (n=509), 77.4% had a PS of 0-1 and 22.6% had a PS of 2+. Overall, median rwPFS was 2.8 mos [95%CI: 2.5–3.1]. Median rwPFS among pts treated in 1L (n=101), 2L (n=318), and third line plus (3L+, n = 254) were 3.8 mos [2.9–4.8], 3.2 mos [2.8–3.5], and 2.1 mos [1.9–2.3], respectively.


In this real-world study of pts with mPDAC treated with a liposomal irinotecan-based regimen, median rwPFS was similar to the median PFS of the pivotal phase III trial despite the fact that pts in the real-world were older, had worse performance scores, and more prior lines of therapy than pts included in the clinical trial. Further studies are needed to characterize factors that influence PFS among pts treated with liposomal irinotecan.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study





G. Kim: Financial Interests, Personal, Advisory Role: Ipsen. P. Cockrum: Financial Interests, Personal, Full or part-time Employment: Ipsen; Financial Interests, Personal, Stocks/Shares: Ipsen. A. Surinach: Financial Interests, Institutional, Advisory Role: Ipsen. S. Wang: Financial Interests, Institutional, Advisory Role: Ipsen. N. Lamarre: Financial Interests, Institutional, Advisory Role: Ipsen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings